You are here

  • Home
  • Archive
  • Volume 79, Issue 9
  • Correction: Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase llb, randomised, double blind, placebo-controlled, dose-ranging study

Article Text

Article menu

See original article:

Download PDFPDF

XML
Miscellaneous
Correction: Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase llb, randomised, double blind, placebo-controlled, dose-ranging study

https://doi.org/10.1136/annrheumdis-2020-216980corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Van der Heijde D, Gensler LS, Deodhar, et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase llb, randomised, double blind, placebo-controlled, dose-ranging study. Ann of Rheum Dis 2020;79:595–4.

    Embedded Image

    The legend for the Figure 1B,C labels should read ‘Placebo/BKZ 320 mg; n=36’ instead of ‘Placebo/BKZ 160 mg; n=36’; and ‘BKZ 320 mg; n=61 (FAS); n=61 (DBS)’ instead of ‘BKZ 160 mg; n=61 (FAS); n=61 (DBS)’.

    A citation to the following paper should be included after first mention of the copyrighted SPARCC instrument: Maksymowych WP, et al. Spondyloarthritis Research Consortium of Canada MRI index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 2005;53(5):703–9. doi: 10.1002/art.21445.

    Linked Articles